Publications by authors named "Donald Mann"

Claim this Profile
D
Development and Implementation of a Medical School Course Integrating Basic, Clinical, and Health Systems Sciences.
Kathryn E Miller, Kelli Qua, Colleen M Croniger, Donald Mann, Karen B Mulloy

J Med Educ Curric Dev· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pregabalin adjunctive therapy for focal onset seizures in children 1 month to <4 years of age: A double-blind, placebo-controlled, video-electroencephalographic trial.
Donald Mann, Jeremias Antinew, Lloyd Knapp, Mary Almas, Jing Liu

Epilepsia· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability, and pharmacokinetics of pregabalin in children with refractory partial seizures: a phase 1, randomized controlled study.
Donald Mann, Jing Liu, Marci L Chew, Howard Bockbrader, Christine W Alvey

Epilepsia· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative structure-activity relationship studies of 1-(5-methylsulfonylpyrid-2-yl)-5-alkyl and (hetero)aryl triazoles and pyrazoles in canine COX inhibition.
Subas M Sakya, Andrei Shavnya, Hengmiao Cheng, Chao Li, Bryson Rast, Donald W Mann

Bioorg Med Chem Lett· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
5
5-Heteroatom substituted pyrazoles as canine COX-2 inhibitors. Part III: molecular modeling studies on binding contribution of 1-(5-methylsulfonyl)pyrid-2-yl and 4-nitrile.
Subas M Sakya, Xinjun Hou, Martha L Minich, Bryson Rast, Andrei Shavnya, Donald W Mann

Bioorg Med Chem Lett· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and SAR of heteroaryl-phenyl-substituted pyrazole derivatives as highly selective and potent canine COX-2 inhibitors.
Hengmiao Cheng, Kristin M Lundy DeMello, Jin Li, Subas M Sakya, Kazuo Ando, Donald W Mann

Bioorg Med Chem Lett· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
5
5-Heteroatom-substituted pyrazoles as canine COX-2 inhibitors: Part 2. Structure-activity relationship studies of 5-alkylethers and 5-thioethers.
Subas M Sakya, Hengmiao Cheng, Kristin M Lundy Demello, Andrei Shavnya, Martha L Minich, Donald W Mann

Bioorg Med Chem Lett· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
5
5-heteroatom substituted pyrazoles as canine COX-2 inhibitors. Part 1: Structure-activity relationship studies of 5-alkylamino pyrazoles and discovery of a potent, selective, and orally active analog.
Subas M Sakya, Kristin M Lundy DeMello, Martha L Minich, Bryson Rast, Andrei Shavnya, Donald W Mann

Bioorg Med Chem Lett· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro and in vivo profile of 2-(3-di-fluoromethyl-5-phenylpyrazol-1-yl)-5-methanesulfonylpyridine, a potent, selective, and orally active canine COX-2 inhibitor.
Jin Li, Michael P Lynch, Kristin Lundy Demello, Subas M Sakya, Hengmiao Cheng, Donald W Mann

Bioorg Med Chem· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a potent, selective and orally active canine COX-2 inhibitor, 2-(3-difluoromethyl-5-phenyl-pyrazol-1-yl)-5-methanesulfonyl-pyridine.
Jin Li, Kristin M Lundy DeMello, Henry Cheng, Subas M Sakya, Brian S Bronk, Donald W Mann

Bioorg Med Chem Lett· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis